FindTrial
Sign In

A Prospective and Observational Study Evaluating the Efficacy and Safety of Coblopasvir in Combination with Sofosbuvir for the Treatment of Hepatitis C in the Northwest Region

A Prospective and Observational Study Evaluating the Efficacy and Safety of Coblopasvir in Combination with Sofosbuvir for the Treatment of Hepatitis C in the Northwest Region

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600115919
Enrollment
Unknown
Registered
2026-01-04
Start date
2023-07-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

Antiviral treatment group:Antiviral therapy with coblopivir combined with sofosbuvir

Sponsors

Tangdu Hospital of the Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: a. Meet the treatment conditions stipulated in the "Guidelines for the Prevention and Treatment of Hepatitis C" (2022 Edition); b. Age >=18 years old; c. Agree to collect clinical data, report adverse events, and conduct follow-up as required;

Exclusion criteria

Exclusion criteria: Exclusion criteria: a. Receive immunosuppressant therapy within 3 months before the start of treatment; b. Patients with end-stage diseases whose life expectancy is less than 12 months; C. Patients whose doctors consider them unsuitable for treatment with the colopivir hydrochloride or sofosbuvir regimens;

Design outcomes

Primary

MeasureTime frame
Quantification of hepatitis C virus;—

Secondary

MeasureTime frame
Total bilirubin;Alanine aminotransferase;Aspartate aminotransferase;Hemoglobin;—

Countries

China

Contacts

Public ContactHong Jiang

Tangdu Hospital of the Fourth Military Medical University

jiangh518@126.com+86 29 8477 8847

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026